MKN-45 Cells
USD$395.00*
Products are shipped frozen on dry ice in cryotubes. Each cryotube typically contains 3 × 106 cells for adherent lines or 5 × 106 cells for suspension lines (refer to the batch CoA for details).
General information
| Description | The MKN-45 cell line is a human gastric cancer cell line, derived from the poorly differentiated adenocarcinoma of the stomach. These cells exhibit characteristics typical of gastric cancer, including rapid growth and a high degree of genetic instability. MKN-45 cells are commonly used in cancer research to study tumor biology, drug resistance mechanisms, and the molecular pathways involved in gastric cancer progression. Their ability to form tumors when xenografted into immunocompromised mice makes them a valuable model for in vivo studies. MKN-45 cells are epithelial in nature and grow as adherent cells in culture. They express various biomarkers relevant to gastric cancer, such as carcinoembryonic antigen (CEA) and E-cadherin, making them useful for diagnostic and therapeutic research. Additionally, MKN-45 cells are often utilized in the evaluation of chemotherapy drugs and targeted therapies due to their responsiveness to treatment and their ability to mimic the clinical behavior of human gastric tumors. Researchers also use this cell line to explore the effects of genetic modifications and to develop new therapeutic strategies aimed at improving patient outcomes in gastric cancer. |
|---|---|
| Organism | Human |
| Tissue | Stomach |
| Disease | Gastric adenocarcinoma |
| Metastatic site | Liver |
| Synonyms | MKN 45, MKN45 |
Characteristics
| Age | 62 years |
|---|---|
| Gender | Female |
| Ethnicity | Japanese |
| Growth properties | Adherent/suspension |
Regulatory Data
| Citation | MKN-45 (Cytion catalog number 300489) |
|---|---|
| Biosafety level | 1 |
| NCBI_TaxID | 9606 |
| CellosaurusAccession | CVCL_0434 |
Biomolecular Data
Handling
| Culture Medium | RPMI 1640, w: 2.0 mM stable Glutamine, w: 2.0 g/L NaHCO3 (Cytion article number 820700a) |
|---|---|
| Supplements | Supplement the medium with 20% heat-inactivated FBS |
| Dissociation Reagent | Accutase |
| Subculturing | Gather the suspension cells in a 15 ml tube and gently wash the adherent cells with PBS lacking calcium and magnesium (use 3-5 ml for T25 flasks and 5-10 ml for T75 flasks). Apply Accutase (1-2 ml for T25 flasks, 2.5 ml for T75 flasks) ensuring full coverage of the cell layer. Allow the cells to incubate at room temperature for 10 minutes. Following incubation, combine and centrifuge both the suspension and adherent cells. After centrifugation, carefully resuspend the cell pellet and transfer the cell suspension into new flasks containing fresh medium. |
| Freeze medium | As a cryopreservation medium, we use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability, or CM-1 (Cytion catalog number 800100), which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress. |
| Thawing and Culturing Cells |
|
| Incubation Atmosphere | 37°C, 5% CO2, humidified atmosphere. |
| Shipping Conditions | Cryopreserved cell lines are shipped on dry ice in validated, insulated packaging with sufficient refrigerant to maintain approximately −78 °C throughout transit. On receipt, inspect the container immediately and transfer vials without delay to appropriate storage. |
| Storage Conditions | For long-term preservation, place vials in vapor-phase liquid nitrogen at about −150 to −196 °C. Storage at −80 °C is acceptable only as a short interim step before transfer to liquid nitrogen. |
Quality Control & Molecular Analysis
| Sterility | Mycoplasma contamination is excluded using both PCR-based assays and luminescence-based mycoplasma detection methods. To ensure there is no bacterial, fungal, or yeast contamination, cell cultures are subjected to daily visual inspections. |
|---|
Certificate of Analysis (CoA)
| Lot Number | Certificate Type | Date | Catalog Number |
|---|---|---|---|
| 300489-061224 | Certificate of Analysis | 25. Mar. 2026 | 300489 |
| 300489-190523 | Certificate of Analysis | 23. May. 2025 | 300489 |